Human evidence record · Ipamorelin
Human pharmacokinetics and GH response to ipamorelin
Ipamorelin showed a roughly 2-hour terminal half-life and dose-related GH responses, with GH peak around 0.67 hours.
Quick read
Human evidence record
What this study tells us
This was a human pharmacology or physiology study. It can show what the compound does to measured biological signals, but it may not establish a meaningful clinical benefit.
Who was studied?
Healthy volunteers
How many?
n=8
What happened?
Ipamorelin showed a roughly 2-hour terminal half-life and dose-related GH responses, with GH peak around 0.67 hours.
What stops us overclaiming?
Does not demonstrate fat loss, muscle gain, recovery, anti-ageing, or long-term safety.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Ipamorelin showed a roughly 2-hour terminal half-life and dose-related GH responses, with GH peak around 0.67 hours.
Study details
Study designDose-escalation pharmacokinetic/pharmacodynamic study
PhasePhase I
PopulationHealthy volunteers
Sample size8
RouteIntravenous infusion
Regimen / exposure4.21-140.45 nmol/kg over 15 minutes
DurationSingle-dose cohorts
ComparatorDose levels
Primary endpoint / questionPK and GH release
Safety resultSmall early exposure study.
Key limitationsDoes not demonstrate fat loss, muscle gain, recovery, anti-ageing, or long-term safety.
Registry / identifierPMID 10496658